Morphan derivatives or salts thereof and medicinal compositions containing the same
AssigneeHisamitsu Pharmaceutical Co., Inc.
InventorsChihiro Kibayashi, Takeshi Miyata, Kazuo Takahama, Hidenao Fukushima
Life of this patent
Estimating the term…
Abstract
Medicinal compositions having an effect of regulating the activation of glycine receptor and novel morphan derivatives. Medicinal compositions comprising morphan derivatives or its salts and a pharmaceutically acceptable carrier. These compositions potentiate or inhibit the activation of glycine receptor, which makes them useful as drugs for the central nervous system. Novel 1- and/or 2-substituted morphan derivatives (2-azabicyclo[3.3.1]nonane derivatives) or salts thereof.
Claims4
A pharmaceutical composition comprising a morphan derivative or a salt thereof represented by formula (1) and a pharmaceutically acceptable carrier thereof:
- wherein
- R1 is hydrogen, an alkyl group having 1-15 carbon atoms, an alkenyl group having 2-20 carbon atoms, and aralkyl group having 7-12 carbon atoms, each of which is optionally substituted with an alkyl group having 1-15 carbon atoms, an alenyl group having 2-20 carbon atoms, a halogen atom, a hydroxy group, or a lower alkoxy group having 1-15 carbon atoms;
- R2 is hydrogen, an alkyl group having 1-15 carbon atoms or an alkenyl group having 2-20 carbon atoms;
- or
- R1 and R2 taken together form an alkylene group having 2-20 carbon atoms, wherein at least one of R1 and R2 is not hydrogen.
A morphan derivative or a salt thereof represented by the following formula (2):
- wherein, R1 is a hydrogen, an alkyl group having 1-15 carbon atoms, an alkenyl group having 2-20 carbon atoms, an aralkyl group having 7-12 carbon atoms, each of which is optionally substituted with an alkyl group having 1-15 carbon atoms, an alkenyl group having 2-20 carbon atoms, a halogen atom, a hydroxyl group, or a lower alkoxy group having 1-15 carbon atoms;
- R2 is a hydrogen, an alkyl group having 1-15 carbon atoms, or an alkenyl group having 2-20 carbon atoms;
- or
- R1 and R2 taken together form an alkylene group having 2-20 carbon atoms, wherein when R1 is hydrogen then R2 is not hydrogen or an alkyl group.
A method for treatment of a disease caused by dysfunction of glycine receptor activation, the method comprising the step of:
- administrating to a patient having disease caused by dysfunction of glycine receptor activation an effective amount of a morphan derivative or a salt thereof represented by formula (1):
- wherein, R1 is hydrogen, an alkyl group having 1-15 carbon atoms, an alkenyl group having 2-20 carbon atoms, and aralkyl group having 7-12 carbon atoms, each of which is optionally substituted with an alkyl group having 1-15 carbon atoms, an alkenyl group having 2-20 carbon atoms, a halogen atom, a hydroxy group, or a lower alkoxy group having 1-15 carbon atoms;
- R2 is hydrogen, an alkyl group having 1-15 carbon atoms or an alkenyl group having 2-20 carbon atoms;
- or
- R1 and R2 taken together form an alkylene group having 2-20 carbon atoms;
- and
- a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.